Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
InnoCare Pharma Ltd. (HK:9969)
HKEX:9969
Holding HK:9969?
Track your performance easily
9969 Stock Chart & Stats
Day’s RangeHK$0 - HK$0
52-Week RangeHK$4.03 - HK$7.49
Previous CloseHK$5.85
Volume9.38M
Average Volume (3M)4.10M
Market Cap
HK$8.79B
Enterprise ValueN/A
Total Cash (Recent Filing)N/A
Total Debt (Recent Filing)N/A
Price to Earnings (P/E)―
Beta1.37
Next Earnings
Nov 11, 2024EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.29
Shares Outstanding249,728,111
10 Day Avg. Volume6,328,166
30 Day Avg. Volume4,097,179
Standard Deviation0.16
R-Squared0.19
Alpha0.00056
Financial Highlights & Ratios
Price to Book (P/B)292.50
Price to Sales (P/S)12.59
Price to Cash Flow (P/CF)-29.00
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
HK$12.00Price Target Upside105.13% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
InnoCare Pharma Ltd. News
PremiumCompany Announcements
InnoCare Advances MS Treatment into Phase 3 Trials
PremiumCompany Announcements
InnoCare Pharma Announces Strong Mid-Year Growth
PremiumCompany Announcements
InnoCare Pharma Sets Date for Financial Update
PremiumCompany Announcements
InnoCare Pharma Awards Employees with Share Scheme
PremiumCompany Announcements
InnoCare Pharma’s AGM: Resolutions Passed with Strong Support
PremiumCompany Announcements
InnoCare’s New Lymphoma Treatment Enters Priority Review
PremiumCompany Announcements
InnoCare CEO Buys Shares, Signals Confidence
PremiumCompany Announcements
InnoCare Pharma Awards Shares to Incentivize StaffOptions Prices
Currently, No data available
---
Ownership Overview
0.00%
Insiders
2.05% Mutual Funds
1.65% Other Institutional Investors
96.30% Public Companies and
Individual Investors
9969 FAQ
What was InnoCare Pharma Ltd.’s price range in the past 12 months?
InnoCare Pharma Ltd. lowest stock price was HK$4.03 and its highest was HK$7.49 in the past 12 months.
What is InnoCare Pharma Ltd.’s market cap?
Currently, no data Available
When is InnoCare Pharma Ltd.’s upcoming earnings report date?
InnoCare Pharma Ltd.’s upcoming earnings report date is Nov 11, 2024 which is in 52 days.
How were InnoCare Pharma Ltd.’s earnings last quarter?
InnoCare Pharma Ltd. released its earnings results on Aug 20, 2024. The company reported -HK$0.176 earnings per share for the quarter, beating the consensus estimate of -HK$0.231 by HK$0.055.
Is InnoCare Pharma Ltd. overvalued?
According to Wall Street analysts InnoCare Pharma Ltd.’s price is currently Undervalued.
Does InnoCare Pharma Ltd. pay dividends?
InnoCare Pharma Ltd. does not currently pay dividends.
What is InnoCare Pharma Ltd.’s EPS estimate?
InnoCare Pharma Ltd.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does InnoCare Pharma Ltd. have?
InnoCare Pharma Ltd. has 1,497,934,200 shares outstanding.
What happened to InnoCare Pharma Ltd.’s price movement after its last earnings report?
InnoCare Pharma Ltd. reported an EPS of -HK$0.176 in its last earnings report, beating expectations of -HK$0.231. Following the earnings report the stock price went up 0.901%.
Which hedge fund is a major shareholder of InnoCare Pharma Ltd.?
Currently, no hedge funds are holding shares in HK:9969
---
InnoCare Pharma Ltd. Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Positive
20 days / 200 days
Momentum
-4.87%
12-Months-Change
Fundamentals
Return on Equity
-6.59%
Trailing 12-Months
Asset Growth
-5.47%
Trailing 12-Months
Company Description
InnoCare Pharma Ltd.
InnoCare Pharma Ltd is a commercial-stage biopharmaceutical company. It discovers, develops, and commercializes drugs for the treatment of cancer and autoimmune diseases. Its commercial drug candidate is Orelabrutinib and clinical-stage drug candidates are ICP-192, ICP-105, ICP-723, and others.
---
9969 Stock 12 Month Forecast
Average Price Target
HK$12.00
▲(105.13% Upside)
Technical Analysis
Budweiser Brewing Co. APAC Ltd.
―
China Putian Food Holding Ltd.
―
NVC International Holdings Ltd.
―
RemeGen Co. Ltd. Class H
―
Best Analysts Covering 9969
1 Year
1 Year Success Rate
1/2 ratings generated profit
1 Year Average Return
-15.80%
reiterated a buy rating 17 days ago
Copying Chris Lui's trades and holding each position for 1 Year would result in 50.00% of your transactions generating a profit, with an average return of -15.80% per trade.
---